Literature DB >> 11033583

A small sample confidence interval approach to assess individual bioequivalence.

T Hyslop1, F Hsuan, D J Holder.   

Abstract

The concept of interchangeable pharmaceutical products has been examined in great detail in the literature. Anderson and Hauck proposed a statistical random coefficient model to study 'switchability', and coined the phrase 'individual bioequivalence' which they defined with a probability-based inequality. Since that paper there has been considerable work and discussion. The Food and Drug Administration has recommended the introduction of individual bioequivalence (IBE) and population bioequivalence (PBE) methods in a draft guidance document. The proposal in the draft guidance includes criteria for IBE and PBE and recommends the use of non-parametric bootstrap 95 per cent upper confidence intervals for the conclusion of either IBE or PBE. However, this method requires intensive computations. We have developed an alternative confidence interval procedure to assess IBE by the FDA recommended criteria. This method utilizes Howe's approximation I to a Cornish-Fisher expansion. Our proposed method is applicable to balanced or unbalanced data in a broad class of extended cross-over designs, and can be easily programmed using readily available software.

Entities:  

Mesh:

Year:  2000        PMID: 11033583     DOI: 10.1002/1097-0258(20001030)19:20<2885::aid-sim553>3.0.co;2-h

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  12 in total

1.  Evaluation of the bioequivalence of highly-variable drugs and drug products.

Authors:  L Tothfalusi; L Endrenyi; K K Midha; M J Rawson; J W Hubbard
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

2.  Limits for the scaled average bioequivalence of highly variable drugs and drug products.

Authors:  Laszlo Tothfalusi; Laszlo Endrenyi
Journal:  Pharm Res       Date:  2003-03       Impact factor: 4.200

3.  Variability in the bioavailability of phenytoin capsules in males and females.

Authors:  M C Meyer; A B Straughn; R M Mhatre; V P Shah; M L Chen; R L Williams; L J Lesko
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

4.  An Exact Procedure for the Evaluation of Reference-Scaled Average Bioequivalence.

Authors:  Laszlo Tothfalusi; Laszlo Endrenyi
Journal:  AAPS J       Date:  2016-01-29       Impact factor: 4.009

5.  Novel scaled bioequivalence limits with leveling-off properties.

Authors:  John Kytariolos; Vangelis Karalis; Panos Macheras; Mira Symillides
Journal:  Pharm Res       Date:  2006-10-18       Impact factor: 4.200

6.  Evaluation of a scaling approach for the bioequivalence of highly variable drugs.

Authors:  Sam H Haidar; Fairouz Makhlouf; Donald J Schuirmann; Terry Hyslop; Barbara Davit; Dale Conner; Lawrence X Yu
Journal:  AAPS J       Date:  2008-08-26       Impact factor: 4.009

Review 7.  Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence.

Authors:  Laszlo Tothfalusi; Laszlo Endrenyi; Alfredo Garcia Arieta
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 8.  Bioequivalence for highly variable drugs: regulatory agreements, disagreements, and harmonization.

Authors:  Laszlo Endrenyi; Laszlo Tothfalusi
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-02-23       Impact factor: 2.745

9.  A comparison of group sequential and fixed sample size designs for bioequivalence trials with highly variable drugs.

Authors:  Sophie I E Knahl; Benjamin Lang; Frank Fleischer; Meinhard Kieser
Journal:  Eur J Clin Pharmacol       Date:  2018-01-23       Impact factor: 2.953

10.  Bioavailability and Bioequivalence in Drug Development.

Authors:  Shein-Chung Chow
Journal:  Wiley Interdiscip Rev Comput Stat       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.